$ cat ./records/gates-foundation-awards-oxitec-4-85-million-to-advance-self-limit-2021.txt
Gates Foundation Awards Oxitec $4.85 Million to Advance Self-Limiting Cattle Tick Program
[RECORD.TXT] · cat --full
Following its initial feasibility grant, the Gates Foundation committed an additional $4.85 million to Oxitec to continue developing a self-limiting genetic solution for cattle tick population control across developing regions. The program targets Rhipicephalus microplus, which has developed resistance to most available acaricides. Unlike chemical insecticides, Oxitec's self-limiting approach is species-specific and does not accumulate in the food chain — a critical advantage for pastoral farming communities in sub-Saharan Africa where cattle are primary household assets.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates-Backed World Mosquito Program Yogyakarta RCT Shows 77% Dengue Reduction in New England Journal of Medicine
Next →
Gates Foundation Funds Oxitec Cattle Tick Biocontrol Feasibility Research
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.